Pharma News
Pharmaceutical
US gastrointestinal (GI) and rare diseases specialist has announced financial guidance for full year 2026, which pleased investors and sent its shares up nearly 27% to $4.27. 3 January 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Nereus (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion from Vanda Pharmaceuticals, whose shares rose as much as 18% to $8.29 on the news. 31 December 2025
Pharmaceutical
With 2025's pharma M&A spend exceeding $150 billion—going by deals reported on by The Pharma Letter—the total was higher than the sum spent in both 2024 and 2023. 30 December 2025
Most Read
Recent news
Pharmaceutical
US pharma major AbbVie plans to acquire a drug delivery device manufacturing facility in Tempe, Arizona, as part of its $10 billion pledge to expand US operations through 2035. The site will be bought from West Pharmaceutical Services and is expected to close by mid-2026. 13 January 2026
Pharmaceutical
The Biotechnology Innovation Organization criticized changes to the US childhood immunization schedule, saying the move lacks a scientific basis and could put children’s health at risk. 13 January 2026
Pharmaceutical
Efforts to return to growth in UK clinical trials are gathering pace, with new figures showing a sharp rise in activity in 2025. 13 January 2026
Pharmaceutical
German CNS-focused specialist Neuraxpharm Group announced the launches in Europe of Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) prolonged-release tablets, two differentiated treatments designed to meet the diverse needs of children and adolescents living with attention deficit and hyperactivity disorder (ADHD). 12 January 2026
Pharmaceutical
Swiss biotech startup FluoSphera has raised 1.23 million euros ($1.34 million) to expand commercial activity and advance its AI-driven imaging platform for preclinical drug testing. The funding round was led by Soulmates Ventures, with participation from a Swiss business angel and IndieBio New York. 12 January 2026
Refine Search
In Brief
Pharmaceutical
29 December 2025 As many people consider lifestyle changes at the start of the year, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is urging the public to make sure any weight-loss medicines they use are safe, effective and legitimate.
Pharmaceutical
24 December 2025 The US Food and Drug Administration (FDA) has approved Accrufer (ferric maltol) capsules to treat pediatric patients ages 10 and older with iron deficiency.
Insights
Pharmaceutical
With 2025's pharma M&A spend exceeding $150 billion—going by deals reported on by The Pharma Letter—the total was higher than the sum spent in both 2024 and 2023. 30 December 2025
Pharmaceutical
The US Food and Drug Administration (FDA) spent much of 2025 in the spotlight. Through steady drug approvals, renewed emphasis on transparency, and concrete steps to modernize its operations, the FDA’s actions this year helped shape expectations for 2026. 30 December 2025
Pharmaceutical
The Russian antitrust regulator – the Federal Antimonopoly Service (FAS) seems to be losing its legal battles with domestic pharmaceutical companies that launched their generics in the market prior to expiration of patents for original drugs, The Pharma Letter’s local correspondent reorts. 30 December 2025
Pharmaceutical
Latin America will need to overhaul how it budgets and finances healthcare if it is to strengthen health systems by 2026 and improve access, quality and efficiency, particularly for patients with chronic and noncommunicable diseases (NCDs), according to a new regional study. 29 December 2025
Pharmaceutical
The year 2025 was a major milestone in the history of rare disease drug development. After decades of slow but steady progress, many long-anticipated drugs were finally approved by regulatory agencies. These new treatments featured innovative mechanisms, easier-to-use dosing regimens, and novel forms of therapy for patients who had previously exhausted their options for treatment. 24 December 2025
Pharmaceutical
An Expert View piece looking forward to next year from the global strategy consultancy's Simon Middleton, head, Europe Life Sciences and partner. 18 December 2025
Pharmaceutical
As a physical embodiment of the ambition of Accord Healthcare to establish itself as a leader in the global health landscape, the company’s new office in Stockley Park, London, is as impressive as it gets. 11 December 2025
Boardroom
Pharmaceutical
AstraZeneca’s new head of Investor Relations, Joris Silon, succeeds Andy Barnett on 1 March 2026, and will be based in Cambridge, UK. 8 January 2026
Pharmaceutical
UK biotech AstronauTx has appointed Adam Rosenberg as chairman of its board, succeeding Tim Edwards, as the company advances its sleep architecture-focused approach to treating Alzheimer’s disease and other neurological disorders. The appointment comes as AstronauTx prepares to move its programs toward early clinical development. 7 January 2026
Pharmaceutical
Abingworth, a transatlantic life sciences investment firm and part of global investment firm Carlyle, today announced several leadership changes. 5 January 2026
Pharmaceutical
US clinical-stage oncology company NanOlogy has appointed David Arthur as chief executive, as it accelerates development of its large surface area microparticle drug platform and prepares a regulatory filing for a rare pediatric brain cancer program. 17 December 2025
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze